ArticleClinical and experimental immunology2017
Low-dose interleukin-2 promotes STAT-5 phosphorylation, T
Article in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 64 citations in OpenAlex.
- An imbalance between CD80 and CD86 levels and CD4 regulatory T cell number and transendocytosis function exists in the liver in autoimmune hepatitis.Clinical and experimental immunology · 2026Article
- Multifaceted Roles of IL-26 in Physiological and Pathological Conditions.International journal of molecular sciences · 2025Review
- Targeted regulatory T cell activation by site-specific PEGylated interleukin-2 mitigates autoimmune inflammation.Journal of translational autoimmunity · 2025Article
- Induction of high numbers of TBMC immunology · 2025Article
- The dual role of TIGIT in regulatory and effector T cells in chronic liver disease.JHEP reports : innovation in hepatology · 2025Article
- Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead.Immunologic research · 2025Review
- Article
- Regulatory T cells in inflamed liver are dysfunctional in murine primary biliary cholangitis.Clinical and experimental immunology · 2024Article
- Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?Frontiers in immunology · 2024Review
- Regulatory T cells in autoimmune kidney diseases and transplantation.Nature reviews. Nephrology · 2023Review
- Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective.Immunotherapy advances · 2023Review
- Phenotypic and Functional Studies of Human Treg Cell Subpopulations.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Similarities and divergences in the metabolism of immune cells in cancer and helminthic infections.Frontiers in oncology · 2023Review
- Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges.Human vaccines & immunotherapeutics · 2022Review
- Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease.Seminars in immunopathology · 2022Review
- Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease.Seminars in immunopathology · 2022Review
- Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms.International journal of molecular sciences · 2021Review
- Article
- Functional heterogeneity of CD4Seminars in immunopathology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.